XML 83 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies - Concentration of Risks (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Concentration Risk      
Cash and cash equivalents $ 2,627,410 $ 3,171,800 $ 3,869,564
Accounts receivable, net $ 676,278 $ 358,027  
Product Revenue | ASD Specialty Healthcare | Customer Concentration Risk      
Concentration Risk      
Concentration risk, percentage 18.00% 12.40%  
Product Revenue | McKesson | Customer Concentration Risk      
Concentration Risk      
Concentration risk, percentage 16.90%    
Product Revenue | Shanghai Pharmaceutical | Customer Concentration Risk      
Concentration Risk      
Concentration risk, percentage 11.10% 14.20%  
Product Revenue | Sinopharm | Customer Concentration Risk      
Concentration Risk      
Concentration risk, percentage   16.00%  
Product Revenue | China Resources | Customer Concentration Risk      
Concentration Risk      
Concentration risk, percentage   11.40%  
Accounts Receivable | Three Largest Customers | Customer Concentration Risk      
Concentration Risk      
Concentration risk, percentage 51.00%    
Accounts Receivable | Four Largest Customers | Customer Concentration Risk      
Concentration Risk      
Concentration risk, percentage   53.20%